We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+13.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$25B
AUM Growth
+$2.35B
Cap. Flow
+$638M
Cap. Flow %
2.55%
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$358M
2
PRLD icon
Prelude Therapeutics
PRLD
+$286M
3
KYMR icon
Kymera Therapeutics
KYMR
+$59.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$55.5M
5
NRIX icon
Nurix Therapeutics
NRIX
+$45.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$94.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.6M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$21.6M
4
INSM icon
Insmed
INSM
+$21.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.35%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$9.25B 36.96%
47,269,424
– –
ONC
2
BeOne Medicines Ltd
ONC
$34.1B
$3.81B 15.22%
13,301,597
+1,524,312
+13% +$358M
INCY icon
3
Incyte
INCY
$25.3B
$2.87B 11.47%
31,999,398
+317
+0% +$30.6K
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.46B
$1.73B 6.91%
41,904,586
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$1B 4.01%
8,760,794
– –
KOD icon
6
Kodiak Sciences
KOD
$2.43B
$731M 2.92%
12,352,175
+777,637
+7% +$39M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12B
$577M 2.31%
7,589,294
– –
ASND icon
8
Ascendis Pharma A/S
ASND
$16.7B
$546M 2.18%
3,540,270
+150,000
+4% +$21.6M
NVTA
9
DELISTED
Invitae Corporation
NVTA
$514M 2.05%
11,850,962
– –
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$410M 1.64%
3,009,344
-154,890
-5% -$16.5M
PRLD icon
11
Prelude Therapeutics
PRLD
$360M
$305M 1.22%
+10,118,636
New +$286M
ARGX icon
12
argenx
ARGX
$55.2B
$268M 1.07%
1,019,557
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$234M 0.94%
1,409,784
– –
IGMS
14
DELISTED
IGM Biosciences
IGMS
$232M 0.93%
3,144,446
+223
+0% +$13.2K
EXAS
15
DELISTED
Exact Sciences
EXAS
$188M 0.75%
1,846,139
– –
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$12.5B
$178M 0.71%
1,499,213
+1
+0% +$109
AMRN
17
Amarin Corp
AMRN
$294M
$135M 0.54%
1,600,943
-123,891
-7% -$14.8M
HRTX icon
18
Heron Therapeutics
HRTX
$92.5M
$88.8M 0.36%
5,994,704
-23,400
-0.4% -$365K
FMTX
19
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$88.3M 0.35%
1,771,509
-228,491
-11% -$9.23M
CERS icon
20
Cerus
CERS
$577M
$85.8M 0.34%
13,713,195
– –
ZYME icon
21
Zymeworks
ZYME
$1.62B
$79.6M 0.32%
1,708,472
– –
INSM icon
22
Insmed
INSM
$22.6B
$73M 0.29%
2,272,712
-752,672
-25% -$21.6M
AXSM icon
23
Axsome Therapeutics
AXSM
$11.9B
$68.4M 0.27%
959,757
-50,000
-5% -$3.9M
NBIX icon
24
Neurocrine Biosciences
NBIX
$18.3B
$65.1M 0.26%
676,975
-230,011
-25% -$26.6M
KYMR icon
25
Kymera Therapeutics
KYMR
$8.68B
$63.3M 0.25%
+1,959,211
New +$59.8M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, Baker Bros. Advisors held 126 positions worth $25B, up 10% from $22.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2020 filing shows 11 new, 17 increased, 63 reduced and 6 closed positions. Its largest new stake was Prelude Therapeutics: 10,118,636 shares worth $305M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2020 buy was Prelude Therapeutics: 10,118,636 shares worth $305M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q3 2020, an estimated $358M increase.
  • Baker Bros. Advisors's biggest Q3 2020 reduction was Neurocrine Biosciences, cutting an estimated $26.6M.
  • Baker Bros. Advisors fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $94.5M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $25B portfolio in Q3 2020.
  • Baker Bros. Advisors opened 11 new positions and closed 6 in Q3 2020.
  • Baker Bros. Advisors's portfolio value rose 10% quarter-over-quarter to $25B.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.